Toshitaka Yukishima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Toshitaka Yukishima has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Kosuke Ebina
Department of Orthopaedic Surgery, The University of Osaka Graduate School of Medicine Faculty of Medicine , Suita
8 shared publications - Seiji Okada
Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan
8 shared publications - Takaaki Noguchi
Department of Orthopaedic Surgery, The University of Osaka Graduate School of Medicine Faculty of Medicine, Suita, Japan
8 shared publications - Yuki Etani
Department of Sports Medical Biomechanics, The University of Osaka Graduate School of Medicine Faculty of Medicine, Suita, Japan
8 shared publications Tomonori Kobayakawa
Kobayakawa Orthopaedics and Rheumatologic Clinic , Fukuroi, Shizuoka
7 shared publications- Kumiko Shimoyama
Division of Rheumatology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan
6 shared publications
Latest Publications
- Open Access
- 8 May 2026
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (5) , 1-10
Impact of oral glucocorticoids on the effectiveness of romosozumab: the multicenter OASIS cohort study
Summary This multicenter retrospective cohort compared romosozumab outcomes between oral glucocorticoid users and non-users. Bone turnover marker responses and lumbar spine bone mineral density gains were similar, whereas total hip bone mineral density gains were smaller among glucocorticoid users. Purpose To investigate the impact of oral glucocorticoids (GC) on the effectiveness of romosozumab by comparing outcomes between GC users and non-users after adjusting for patient background. Methods This multicenter, retrospective cohort study analyzed patients who completed 12 months of therapy (n = 428). Inverse probability of treatment weighting was employed to construct a pseudo-population with balanced baseline characteristics, yielding 40 GC users and 39.8 non-users (95.3% female, mean age 76.6 years; mean lumbar spine T-score -2.7; mean GC dose 5.4 mg/day [prednisolone equivalent]). Percentage changes in bone turnover markers (BTMs) and bone mineral density (BMD) over 12 months were compared between groups. Factors affecting BMD changes were identified using multivariable analysis. Results GC use did not significantly affect the changes in PINP and TRACP-5b levels. The 12-month increase in lumbar spine BMD was comparable between groups (GC users 9.7% vs. non-users 10.7%; P = 0.55). In contrast, the increase in total hip BMD was significantly lower in GC users compared with non-users (2.8% vs. 5.6%; P = 0.003). Multivariable analysis revealed that baseline PINP was significantly associated with the BMD increase at the lumbar spine, whereas daily GC dose was a significant factor for the total hip. Conclusion Oral GC use did not significantly affect changes in BTMs or BMD increases at the lumbar spine. Smaller gains in total hip BMD were observed in GC users, which may have reflected not only GC use but also underlying disease-related factors.
- 8 May 2026
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (5) , 1-10
Open AccessImpact of oral glucocorticoids on the effectiveness of romosozumab: the multicenter OASIS cohort study
Summary This multicenter retrospective cohort compared romosozumab outcomes between oral glucocorticoid users and non-users. Bone turnover marker responses and lumbar spine bone mineral density gains were similar, whereas total hip bone mineral density gains were smaller among glucocorticoid users. Purpose To investigate the impact of oral glucocorticoids (GC) on the effectiveness of romosozumab by comparing outcomes between GC users and non-users after adjusting for patient background. Methods This multicenter, retrospective cohort study analyzed patients who completed 12 months of therapy (n = 428). Inverse probability of treatment weighting was employed to construct a pseudo-population with balanced baseline characteristics, yielding 40 GC users and 39.8 non-users (95.3% female, mean age 76.6 years; mean lumbar spine T-score -2.7; mean GC dose 5.4 mg/day [prednisolone equivalent]). Percentage changes in bone turnover markers (BTMs) and bone mineral density (BMD) over 12 months were compared between groups. Factors affecting BMD changes were identified using multivariable analysis. Results GC use did not significantly affect the changes in PINP and TRACP-5b levels. The 12-month increase in lumbar spine BMD was comparable between groups (GC users 9.7% vs. non-users 10.7%; P = 0.55). In contrast, the increase in total hip BMD was significantly lower in GC users compared with non-users (2.8% vs. 5.6%; P = 0.003). Multivariable analysis revealed that baseline PINP was significantly associated with the BMD increase at the lumbar spine, whereas daily GC dose was a significant factor for the total hip. Conclusion Oral GC use did not significantly affect changes in BTMs or BMD increases at the lumbar spine. Smaller gains in total hip BMD were observed in GC users, which may have reflected not only GC use but also underlying disease-related factors.
- Open Access
- 1 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0344867
Serum presepsin level reflects macrophage activation and hemophagocytosis in bone marrow
Background: Presepsin (soluble CD14 subtype) is a clinically used diagnostic biomarker for sepsis. It is secreted into the blood by activated macrophages, and serum concentrations are elevated in patients with sepsis. Previous reports suggest that presepsin may be secreted into the peripheral blood due to increased hemophagocytosis. However, the relationship between serum presepsin concentration and hemophagocytosis, as evidenced by bone marrow aspiration for diagnosing hemophagocytic lymphohistiocytosis, is not well understood. Therefore, we investigated the relationship between serum presepsin level and hemophagocytes in bone marrow. Methods: We retrospectively analyzed 61 patients with serum presepsin level who underwent bone marrow aspirations. We examined the relationship between serum presepsin level and other laboratory findings, including the number of macrophages and the percentage of hemophagocytes in their bone marrow. Macrophages and hemophagocytes were counted using bone marrow smears. Immunostaining of bone marrow aspirate smears was performed using a CD14 antibody to evaluate the relationship between serum presepsin level and hemophagocytes in the bone marrow. Results: Serum presepsin level correlated with inflammatory markers (C-reactive protein and D-dimer) and markers related to hemophagocytosis (lactate dehydrogenase, ferritin, red blood cell count, hemoglobin, hematocrit, number of macrophages, and percentage of hemophagocytes in the bone marrow). The percentage of hemophagocytes in the bone marrow was positively correlated with serum presepsin level (r = 0.435, p < 0.001) and with ferritin (r = 0.438, p = 0.015), both of which were elevated during hemophagocytosis. CD14 expression is attenuated in hemophagocytes in bone marrow and lymph nodes. Conclusion: These findings suggest that serum presepsin is released by hemophagocytes and reflects the activation of macrophages and hemophagocytosis in bone marrow.
- 1 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0344867
Open AccessSerum presepsin level reflects macrophage activation and hemophagocytosis in bone marrow
Background: Presepsin (soluble CD14 subtype) is a clinically used diagnostic biomarker for sepsis. It is secreted into the blood by activated macrophages, and serum concentrations are elevated in patients with sepsis. Previous reports suggest that presepsin may be secreted into the peripheral blood due to increased hemophagocytosis. However, the relationship between serum presepsin concentration and hemophagocytosis, as evidenced by bone marrow aspiration for diagnosing hemophagocytic lymphohistiocytosis, is not well understood. Therefore, we investigated the relationship between serum presepsin level and hemophagocytes in bone marrow. Methods: We retrospectively analyzed 61 patients with serum presepsin level who underwent bone marrow aspirations. We examined the relationship between serum presepsin level and other laboratory findings, including the number of macrophages and the percentage of hemophagocytes in their bone marrow. Macrophages and hemophagocytes were counted using bone marrow smears. Immunostaining of bone marrow aspirate smears was performed using a CD14 antibody to evaluate the relationship between serum presepsin level and hemophagocytes in the bone marrow. Results: Serum presepsin level correlated with inflammatory markers (C-reactive protein and D-dimer) and markers related to hemophagocytosis (lactate dehydrogenase, ferritin, red blood cell count, hemoglobin, hematocrit, number of macrophages, and percentage of hemophagocytes in the bone marrow). The percentage of hemophagocytes in the bone marrow was positively correlated with serum presepsin level (r = 0.435, p < 0.001) and with ferritin (r = 0.438, p = 0.015), both of which were elevated during hemophagocytosis. CD14 expression is attenuated in hemophagocytes in bone marrow and lymph nodes. Conclusion: These findings suggest that serum presepsin is released by hemophagocytes and reflects the activation of macrophages and hemophagocytosis in bone marrow.
- 12 February 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (3)
Effectiveness of denosumab, teriparatide and romosozumab for glucocorticoid-induced osteoporosis: a propensity score-matched cohort study
Objectives: To investigate the effectiveness of denosumab (DMAb), teriparatide (TPTD) and romosozumab (ROMO) in patients with glucocorticoid-induced osteoporosis (GIOP). Method: This multicenter, retrospective cohort study employed propensity score matching to select 42 patients per treatment group [92.1% female, mean age 73.5 years, 35.7% osteoporosis treatment naive, oral glucocorticoids (prednisolone equivalent) 5.4 mg/day, baseline bone mineral density (BMD) T-scores: lumbar spine (LS) −2.5]. Bone turnover markers (BTMs) and BMD were assessed over 12 months. Results: DMAb suppressed BTM levels, whereas TPTD increased them. ROMO showed a dual effect, with increased and decreased levels of formation and resorption markers, respectively. At 12 months, LS BMD increases were greater with ROMO (9.5%) and tended to be higher with TPTD (8.4%) compared with DMAb (4.4%) (P = 0.008 for ROMO vs DMAb). At 6 months, total hip BMD increased with DMAb (2.6%) and ROMO (1.8%) but decreased with TPTD (−0.6%; P = 0.01 for DMAb vs TPTD; P = 0.042 for ROMO vs TPTD); no significant differences were observed at 12 months (3.2%, 2.6%, 2.2%, respectively). DMAb showed significant increases in femoral neck BMD at 6 (2.2%) and 12 (3.0%) months from baseline. Conclusion: BTM levels reflected expected pharmacological actions of each drug. ROMO showed greater LS BMD gains than DMAb, while TPTD demonstrated a similar response, whereas DMAb may provide earlier benefits at cortical-rich sites. These findings underscore the importance of site-specific, individualized treatment strategies for GIOP.
- 12 February 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (3)
Effectiveness of denosumab, teriparatide and romosozumab for glucocorticoid-induced osteoporosis: a propensity score-matched cohort study
Objectives: To investigate the effectiveness of denosumab (DMAb), teriparatide (TPTD) and romosozumab (ROMO) in patients with glucocorticoid-induced osteoporosis (GIOP). Method: This multicenter, retrospective cohort study employed propensity score matching to select 42 patients per treatment group [92.1% female, mean age 73.5 years, 35.7% osteoporosis treatment naive, oral glucocorticoids (prednisolone equivalent) 5.4 mg/day, baseline bone mineral density (BMD) T-scores: lumbar spine (LS) −2.5]. Bone turnover markers (BTMs) and BMD were assessed over 12 months. Results: DMAb suppressed BTM levels, whereas TPTD increased them. ROMO showed a dual effect, with increased and decreased levels of formation and resorption markers, respectively. At 12 months, LS BMD increases were greater with ROMO (9.5%) and tended to be higher with TPTD (8.4%) compared with DMAb (4.4%) (P = 0.008 for ROMO vs DMAb). At 6 months, total hip BMD increased with DMAb (2.6%) and ROMO (1.8%) but decreased with TPTD (−0.6%; P = 0.01 for DMAb vs TPTD; P = 0.042 for ROMO vs TPTD); no significant differences were observed at 12 months (3.2%, 2.6%, 2.2%, respectively). DMAb showed significant increases in femoral neck BMD at 6 (2.2%) and 12 (3.0%) months from baseline. Conclusion: BTM levels reflected expected pharmacological actions of each drug. ROMO showed greater LS BMD gains than DMAb, while TPTD demonstrated a similar response, whereas DMAb may provide earlier benefits at cortical-rich sites. These findings underscore the importance of site-specific, individualized treatment strategies for GIOP.
- 24 December 2025
- Published by Springer Nature in Rheumatology International
- Vol. 46 (1) , 24
MRI-guided muscle biopsy improves diagnostic yield in small- to medium-vessel vasculitis: a retrospective single-center study
To evaluate the utility of magnetic resonance imaging (MRI)-guided muscle biopsy (MB) in diagnosing small- to medium-vessel vasculitis. We retrospectively included patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) or polyarteritis nodosa (PAN) between April 2020 and March 2025 who underwent MRI and MB. The primary outcome was the diagnostic sensitivity of MRI-guided MB for AAV and PAN. The secondary outcome was the diagnostic sensitivity for PAN alone. MB was considered positive when it demonstrated either necrotizing vasculitis or non-necrotizing vasculitis. Eighteen patients who underwent MRI and MB were included: 11 patients had AAV and 7 had PAN. The median interval between MRI and MB was 3.5 days. The mean Birmingham Vasculitis Activity Score was 13.6. Muscle pain was observed in 11 patients; however, none of the patients exhibited elevated creatine kinase levels. The sensitivity of MB for diagnosing AAV and PAN was 83.3% (15/18; 95% confidence intervals [CI] 58.6–96.4%), whereas that for PAN alone was 85.7% (6/7; 95% CI 42.1–96.3%). No biopsy-related complications were observed. There were no apparent differences in clinical characteristics between the MB-positive and MB-negative groups. MRI-guided MB may represent a diagnostic option for small- to medium-vessel vasculitis, even in patients without muscle pain or when other suitable biopsy sites are unavailable. Although this was a small exploratory retrospective single-center study, these findings should be validated in larger multicenter prospective studies.
- 24 December 2025
- Published by Springer Nature in Rheumatology International
- Vol. 46 (1) , 24
MRI-guided muscle biopsy improves diagnostic yield in small- to medium-vessel vasculitis: a retrospective single-center study
To evaluate the utility of magnetic resonance imaging (MRI)-guided muscle biopsy (MB) in diagnosing small- to medium-vessel vasculitis. We retrospectively included patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) or polyarteritis nodosa (PAN) between April 2020 and March 2025 who underwent MRI and MB. The primary outcome was the diagnostic sensitivity of MRI-guided MB for AAV and PAN. The secondary outcome was the diagnostic sensitivity for PAN alone. MB was considered positive when it demonstrated either necrotizing vasculitis or non-necrotizing vasculitis. Eighteen patients who underwent MRI and MB were included: 11 patients had AAV and 7 had PAN. The median interval between MRI and MB was 3.5 days. The mean Birmingham Vasculitis Activity Score was 13.6. Muscle pain was observed in 11 patients; however, none of the patients exhibited elevated creatine kinase levels. The sensitivity of MB for diagnosing AAV and PAN was 83.3% (15/18; 95% confidence intervals [CI] 58.6–96.4%), whereas that for PAN alone was 85.7% (6/7; 95% CI 42.1–96.3%). No biopsy-related complications were observed. There were no apparent differences in clinical characteristics between the MB-positive and MB-negative groups. MRI-guided MB may represent a diagnostic option for small- to medium-vessel vasculitis, even in patients without muscle pain or when other suitable biopsy sites are unavailable. Although this was a small exploratory retrospective single-center study, these findings should be validated in larger multicenter prospective studies.
- 19 March 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (5) , 931-932
Author response to letter to the editor, (OSIN-D-25–00227) “From bisphosphonates to advanced therapies: a critical review of osteoporosis treatment strategies”
- 19 March 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (5) , 931-932
Author response to letter to the editor, (OSIN-D-25–00227) “From bisphosphonates to advanced therapies: a critical review of osteoporosis treatment strategies”